Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.79 USD | +1.52% | +4.57% | +6.33% |
Financials (USD)
Sales 2024 * | 5.59M | Sales 2025 * | 3.67M | Capitalization | 42.54M |
---|---|---|---|---|---|
Net income 2024 * | -63M | Net income 2025 * | -66M | EV / Sales 2024 * | 5.75 x |
Net cash position 2024 * | 10.4M | Net Debt 2025 * | 29.1M | EV / Sales 2025 * | 19.5 x |
P/E ratio 2024 * |
-0.72
x | P/E ratio 2025 * |
-0.76
x | Employees | 55 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 85.57% |
Latest transcript on Cara Therapeutics, Inc.
1 day | +1.52% | ||
1 week | +4.57% | ||
Current month | +5.07% | ||
1 month | -4.30% | ||
3 months | +36.94% | ||
6 months | -40.60% | ||
Current year | +6.33% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 54 | 18-08-05 | |
Ryan Maynard
DFI | Director of Finance/CFO | 54 | 22-09-11 |
Scott Terrillion
CMP | Compliance Officer | 61 | 16-10-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Martin Vogelbaum
CHM | Chairman | 60 | 10-06-30 |
Jeffrey Ives
BRD | Director/Board Member | 73 | 14-07-15 |
Helen Boudreau
BRD | Director/Board Member | 58 | 23-08-01 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
11.20% | 35 M€ | +29.98% | - | |
1.29% | 13 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-06 | 0.79 | +1.52% | 353 227 |
24-05-03 | 0.7782 | +0.78% | 159,125 |
24-05-02 | 0.7722 | +1.79% | 192,965 |
24-05-01 | 0.7586 | +0.89% | 190,442 |
24-04-30 | 0.7519 | -0.48% | 192,151 |
Delayed Quote Nasdaq, May 06, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+6.33% | 42.54M | |
-3.89% | 88.14B | |
+1.45% | 40.51B | |
-14.43% | 31.67B | |
+51.20% | 24.62B | |
-14.85% | 15.65B | |
-13.87% | 12.07B | |
-7.87% | 11.97B | |
-39.40% | 11.61B | |
+5.62% | 8.81B |
- Stock Market
- Equities
- CARA Stock